Hypertension, angiotensin II, aldosterone, and race.
Ben-Yehuda
Ori
O
D000450:Aldosterone / Q000097:blood; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D044383:Black People; D000077545:Eplerenone; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000208:ethnology; D019808:Losartan / Q000627:therapeutic use*; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D012083:Renin / Q000097:blood / Q000187:drug effects; D012084:Renin-Angiotensin System / Q000187:drug effects; D013148:Spironolactone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016896:Treatment Outcome; D044465:White People
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000450:Aldosterone; D000077545:Eplerenone; D012083:Renin; D019808:Losartan